Fundamental value investors, who intend to manage their stock portfolios like Warren Buffett and Peter Lynch, now find it more difficult to ferret out individual stocks that currently experience substantial market undervaluation. During the current economic boom, a rising tide lifts all boats, especially for tech firms, banks, and energy companies. Written by Parnassus equity portfolio managers, this article seems to emphasize the general observation that most health care and biotech stocks seem reasonably cheap relative to most market benchmarks.

However, we believe it is not likely for these health care and biotech stocks to bounce back during the current Trump administration. President Trump seeks to cut medical costs and drug prices substantially in the next few years to make health care more affordable for the American middle class without Obamacare.

The resultant competitive landscape for these health care and biotech firms becomes a unique one with fewer moats across the pharmaceutical industry spectrum. This key motif serves as part of the broader mantra of Trumponomics.

This analysis draws investor attention to big banks with minimal financial stress (after they pass the Federal Reserve's macroprudential stress test), tech stocks with average P/E ratios well above 25x (especially for FAMGA aka Facebook, Apple, Microsoft, Google, and Amazon), and energy companies (such as PSX or Phillips 66 that Warren Buffett has included as a new value stock in Berkshire Hathaway's portfolio in recent times).

The law of inadvertent consequences counsels caution.